Maxim Maintains Buy On Soligenix Following Preclinical Results
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Soligenix Inc (OTC:SNGX) with a $3.00 price target, following the release of the company’s preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate lethal aerosol exposure model.
Kolbert said, “With active Biodefense programs in anthrax, ricin, and acute radiation syndrome, we see Soligenix as positioned to capture DOD/BARDA contracts. In a crisis, we could see value realized as investors focus on which companies have solutions, in much the way recent events in West Africa have focused attention on those companies developing Medical Counter Measures (MCM) to Ebola.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 10.2% and a 49.5% success rate. Kolbert has a -9.2% average return when recommending SNGX, and is ranked #355 out of 3284 analysts.